Transition to EU HTA – Consequences of an existence of national and EU HTA in parallel
Transition to EU-HTA – Consequences of an existance of national and EU-HTA in parallel Regulation (EU) 2021/2282 Article 7 (1) of Regulation (EU) 2021/2282 specifies when a health technology must undergo a Joint Clinical Assessment (JCA). Paragraph 1a stipulates that the time of initial market authorization application (MAA) is decisive. A JCA of the